Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club

被引：48

作者：

Boonen, S

Body, JJ

Boutsen, Y

Devogelaer, JP

Goemaere, S

Kaufman, JM

Rozenberg, S

Reginster, JY

机构：

[1] CHU Ctr Ville, Policlin L BRULL, Bone & Cartilage Metab Res Unit, B-4020 Liege, Belgium

[2] Katholieke Univ Leuven, Ctr Metab Bone Dis, Louvain, Belgium

[3] Free Univ Brussels, Dept Internal Med, Brussels, Belgium

[4] Catholic Univ Louvain, Mont Godinne Univ Hosp, Dept Rheumatol, Brussels, Belgium

[5] Catholic Univ Louvain, St Luc Univ Hosp, Dept Rheumatol, Brussels, Belgium

[6] Univ Ghent, Dept Rheumatol & Endocrinol, B-9000 Ghent, Belgium

[7] Univ Ghent, Dept Endocrinol, B-9000 Ghent, Belgium

[8] Free Univ Brussels, Dept Obstet & Gynaecol, Brussels, Belgium

[9] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium

来源：

OSTEOPOROSIS INTERNATIONAL | 2005年 / 16卷 / 03期

关键词：

evidence-based; guidelines; osteoporosis; treatment;

D O I：

10.1007/s00198-004-1812-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：239 / 254

页数：16

共 114 条

[1] Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study [J].

Albrand, G ;

Munoz, F ;

Sornay-Rendu, E ;

DuBoeuf, F ;

Delmas, PD .

BONE, 2003, 32 (01) :78-85

[2]

Alekel DL, 2000, AM J CLIN NUTR, V72, P844

[3] Ipriflavone in the treatment of postmenopausal osteoporosis - A randomized controlled trial [J].

Alexandersen, P ;

Toussaint, A ;

Christiansen, C ;

Devogelaer, JP ;

Roux, C ;

Fechtenbaum, J ;

Gennari, C ;

Reginster, JY .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (11) :1482-1488

[4]

[Anonymous], 1994, JAMA, V272, P1942

[5] Costs induced by hip fractures:: A prospective controlled study in Belgium [J].

Autier, P ;

Haentjens, P ;

Bentin, J ;

Baillon, JM ;

Grivegnée, AR ;

Colson, MC ;

Boonen, S .

OSTEOPOROSIS INTERNATIONAL, 2000, 11 (05) :373-380

[6] Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [J].

Barrett-Connor, E ;

Grady, D ;

Sashegyi, A ;

Anderson, PW ;

Cox, DA ;

Hoszowski, K ;

Rautaharju, P ;

Harper, KD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (07) :847-857

[7] Randomised controlled trial of hip protectors for the prevention of second hip fractures [J].

Birks, YF ;

Hildreth, R ;

Campbell, P ;

Sharpe, C ;

Torgerson, DJ ;

Watt, I .

AGE AND AGEING, 2003, 32 (04) :442-444

[8] Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].

Bjarnason, NH ;

Sarkar, S ;

Duong, T ;

Mitlak, B ;

Delmas, PD ;

Christiansen, C .

OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :922-930

[9] The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].

Black, DM ;

Greenspan, SL ;

Ensrud, KE ;

Palermo, L ;

McGowan, JA ;

Lang, TF ;

Garnero, P ;

Bouxsein, ML ;

Bilezikian, JP ;

Rosen, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215

[10] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

← 1 2 3 4 5 6 7 8 9 10 →